# Ascending Single-dose Study to Evaluate TVB-2640 in Chinese Healthy Subjects

> **NCT04352361** · PHASE1 · COMPLETED · sponsor: **Ascletis Pharmaceuticals Co., Ltd.** · enrollment: 34 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** TVB-2640
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04352361
- **Lead sponsor:** Ascletis Pharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-04-02
- **Primary completion:** 2020-04-29
- **Final completion:** 2020-04-29
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2020-07-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04352361

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04352361, "Ascending Single-dose Study to Evaluate TVB-2640 in Chinese Healthy Subjects". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04352361. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*